The Canadian medical profession has a long history of allying itself with the Canadian pharmaceutical industry. This alliance exists on two levels: medical associations and medical journals. As a result of the alliance the traditional emphasis of the medical profession on the primacy of the welfare of the patient has been subverted in favor of the profit motive of the drug industry. Elements of the medical profession promote useless pharmaceutical research, poor physician prescribing, and physician involvement in educational activities controlled by the industry. Specific reforms to loosen the alliance are outlined, but ultimately the alliance will only be broken when the values of Canadian physicians change.
Get full access to this article
View all access options for this article.
References
1.
WoodsD.PMAC to spend almost $1 million annually to reach “stakeholders.”Can. Med. Assoc. J.134: 1387–1389, 1986.
2.
Commission of Inquiry on the Pharmaceutical Industry. Report. Supply and Services Canada, Ottawa, 1985.
3.
Government involvement in health care. Can. Pharmaceut. J.104: 26–27, July 1971.
4.
Pharmaceutical industry studies current, future trends. Can. Pharmaceut. J.110: 27–29, May 1977.
5.
WallaceJ. D.APMR? Now what would that be. Can. Med. Assoc. J.108: 1302, 1973.
6.
Can. Med. Assoc. J.119: 1336, 1978.
7.
RegushN.MDs not always expert on drugs they prescribe. Montreal Gazette, October 26, 1982, pp. A1, A8.
8.
SawatskyJ.CashoreH.Inside dope: The multi-million dollar sellout of Canada's generic drug industry. This Magazine, August/September 1986, pp. 4–12.
9.
Report of the committee on pharmacy. Can. Med. Assoc. J.93: 459, 1965.
10.
Association submits second brief on non-medical use of drugs to LeDain Commission. Can. Med. Assoc. J.104: 738–741, 1971.
11.
Canada, House of Commons, Special Committee on Drug Costs and Prices. Minutes of Proceedings and Evidence. No. 6, p. 413. Queen's Printer, Ottawa, June 28, 1966.
12.
LangR. W.The Politics of Drugs, pp. 109–110. Saxon House, Westmead, England, 1974.
13.
BurstallM. L.DunningJ. H.LakeA.Multinational Enterprises, Governments and Technology–The Pharmaceutical Industry. Organization for Economic Cooperation and Development, Paris, 1981.
14.
Canadian Medical Association. Brief to the Commission of Inquiry on the Pharmaceutical Industry. August 15, 1984.
15.
Pharmaceutical Manufacturers Association of Canada. Submission to the Commission of Inquiry on the Pharmaceutical Industry. August 1984.
16.
IacobacciM.Pressure groups and the federal government: The case of pharmaceutical lobbies regarding compulsory licensing. Ottawa, May 1985 (unpublished).
17.
Canadian Medical Association. Brief to the House of Commons Legislative Committee on Bill C-22: An Act to Amend the Patent Act. February 11, 1987.
18.
General Council votes to support Patent Act amendments affecting drugs. Can. Med. Assoc. J.137: 643, 1987.
HemminkiE.The effect of a doctor's personal characteristics and working circumstances on the prescribing of psychotropic drugs. Med. Care12: 351–357, 1974.
58.
LinnL. S.DavisM. S.Physicians' orientation toward the legitimacy of drug use and their preferred source of new drug information. Soc. Sci. Med.6: 199–203, 1972.
59.
StolleyP. D.The relationship between physician characteristics and prescribing appropriateness. Med. Care10: 17–28, 1972.
60.
BeckerM. H.Differential education concerning therapeutics and resultant physician prescribing patterns. J. Med. Educ.47: 118–127, 1972.
61.
MapesR.Aspects of British general practitioners' prescribing. Med. Care15: 371–381, 1977.
62.
HaayerF.Rational prescribing and sources of information. Soc. Sci. Med.16: 2017–2023, 1982.
63.
BlondeelL.Prescription Behaviour of 358 Flemish General Practitioners. Paper presented at the International Society of General Medicine meeting, Prague, 1987.
